Literature DB >> 24876930

Bisphosphonates and bone quality.

Michael Pazianas1, Stefan van der Geest2, Paul Miller3.   

Abstract

Bisphosphonates (BPs) are bone-avid compounds used as first-line medications for the prevention and treatment of osteoporosis. They are also used in other skeletal pathologies such as Paget's and metastatic bone disease. They effectively reduce osteoclast viability and also activity in the resorptive phase of bone remodelling and help preserve bone micro-architecture, both major determinants of bone strength and ultimately of the susceptibility to fractures. The chemically distinctive structure of each BP used in the clinic determines their unique affinity, distribution/penetration throughout the bone and their individual effects on bone geometry, micro-architecture and composition or what we call 'bone quality'. BPs have no clinically significant anabolic effects. This review will touch upon some of the components of bone quality that could be affected by the administration of BPs.

Entities:  

Year:  2014        PMID: 24876930      PMCID: PMC4037878          DOI: 10.1038/bonekey.2014.24

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  108 in total

Review 1.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

2.  Effects of non-enzymatic glycation on cancellous bone fragility.

Authors:  S Y Tang; U Zeenath; D Vashishth
Journal:  Bone       Date:  2006-12-21       Impact factor: 4.398

3.  Age-related changes in the tensile properties of cortical bone. The relative importance of changes in porosity, mineralization, and microstructure.

Authors:  R W McCalden; J A McGeough; M B Barker; C M Court-Brown
Journal:  J Bone Joint Surg Am       Date:  1993-08       Impact factor: 5.284

Review 4.  Effects of ibandronate on bone quality: preclinical studies.

Authors:  F Bauss; D W Dempster
Journal:  Bone       Date:  2006-09-22       Impact factor: 4.398

5.  Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.

Authors:  Erich Durchschlag; Eleftherios P Paschalis; Ruth Zoehrer; Paul Roschger; Peter Fratzl; Robert Recker; Roger Phipps; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

6.  Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss.

Authors:  J Ignacio Aguirre; Lilian I Plotkin; Scott A Stewart; Robert S Weinstein; A Michael Parfitt; Stavros C Manolagas; Teresita Bellido
Journal:  J Bone Miner Res       Date:  2006-04-05       Impact factor: 6.741

7.  Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.

Authors:  R Lindsay; N B Watts; J L Lange; P D Delmas; S L Silverman
Journal:  Osteoporos Int       Date:  2013-04-24       Impact factor: 4.507

8.  Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.

Authors:  Babul Borah; Thomas E Dufresne; Paula A Chmielewski; Gary J Gross; Marla C Prenger; Roger J Phipps
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

9.  High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.

Authors:  Samantha Pozzi; Sonia Vallet; Siddhartha Mukherjee; Diana Cirstea; Nileshwari Vaghela; Loredana Santo; Eyal Rosen; Hiroshi Ikeda; Yutaka Okawa; Tanyel Kiziltepe; Jesse Schoonmaker; Wanling Xie; Teru Hideshima; Edie Weller; Mary L Bouxsein; Nikhil C Munshi; Kenneth C Anderson; Noopur Raje
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

10.  Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs.

Authors:  M Saito; S Mori; T Mashiba; S Komatsubara; K Marumo
Journal:  Osteoporos Int       Date:  2008-03-29       Impact factor: 5.071

View more
  34 in total

1.  Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.

Authors:  Ranya Elsayed; Pheba Abraham; Mohamed E Awad; Zoya Kurago; Balasudha Baladhandayutham; Gary M Whitford; David H Pashley; Charles E McKenna; Mohammed E Elsalanty
Journal:  Bone       Date:  2018-02-09       Impact factor: 4.398

Review 2.  Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.

Authors:  Jordan C Villa; Arianna Gianakos; Joseph M Lane
Journal:  HSS J       Date:  2015-12-09

3.  Multiplexed Molecular Imaging Strategy Integrated with RNA Sequencing in the Assessment of the Therapeutic Effect of Wharton's Jelly Mesenchymal Stem Cell-Derived Extracellular Vesicles for Osteoporosis.

Authors:  Cheng-Hsiu Lu; Yi-An Chen; Chien-Chih Ke; Sain-Jhih Chiu; Fong-Shya Jeng; Chao-Cheng Chen; Ya-Ju Hsieh; Bang-Hung Yang; Chi-Wei Chang; Feng-Sheng Wang; Ren-Shyan Liu
Journal:  Int J Nanomedicine       Date:  2021-11-30

4.  Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate.

Authors:  Ke Lu; Qin Shi; Ya-Qin Gong; Jia-Wei Shao; Chong Li
Journal:  Osteoporos Int       Date:  2022-08-03       Impact factor: 5.071

5.  Young's modulus and hardness of human trabecular bone with bisphosphonate treatment durations up to 20 years.

Authors:  D Pienkowski; C L Wood; H H Malluche
Journal:  Osteoporos Int       Date:  2018-11-28       Impact factor: 4.507

Review 6.  MANAGEMENT OF ENDOCRINE DISEASE: Bone complications of bariatric surgery: updates on sleeve gastrectomy, fractures, and interventions.

Authors:  Kristen M Beavers; Katelyn A Greene; Elaine W Yu
Journal:  Eur J Endocrinol       Date:  2020-11       Impact factor: 6.664

7.  Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates.

Authors:  J Ward; C Wood; K Rouch; D Pienkowski; H H Malluche
Journal:  Osteoporos Int       Date:  2016-07-22       Impact factor: 4.507

Review 8.  Use of fractal analysis in dental images for osteoporosis detection: a systematic review and meta-analysis.

Authors:  R Franciotti; M Moharrami; A Quaranta; M E Bizzoca; A Piattelli; G Aprile; V Perrotti
Journal:  Osteoporos Int       Date:  2021-01-28       Impact factor: 4.507

9.  Small Extracellular Vesicles Derived from Adipose Tissue Prevent Bisphosphonate-Related Osteonecrosis of the Jaw by Promoting Angiogenesis.

Authors:  Jiao Huang; Lin Wang; Weidong Tian
Journal:  Int J Nanomedicine       Date:  2021-05-07

Review 10.  Biomechanical Properties of Metastatically Involved Osteolytic Bone.

Authors:  Cari M Whyne; Dallis Ferguson; Allison Clement; Mohammedayaz Rangrez; Michael Hardisty
Journal:  Curr Osteoporos Rep       Date:  2020-10-19       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.